EffRx partners with Andrus to expand footprint Russia and CIS

Swiss drug delivery specialist EffRx Pharmaceuticals has signed an agreement with Moscow-based Andrus Ltd to develop products for commercialization in Russia and CIS (Commonwealth of Independent States) countries.

"We are excited to further expand the footprint of our proprietary technologies with the development of novel therapeutic entities for these fast-growing emerging markets" said Christer Rosén, EffRx chief executive, adding: "Although our core focus within EffRx is to develop our own un-encumbered orphan products we will still utilize this business segment to generate a steady increasing revenue stream."

Under the terms of the deal, EffRx will develop novel, tailored therapeutic entities (six products are presently identified) for commercialization by Andrus in Russia and CIS countries.